Table 6.
Reported vaccine effectiveness against vaccine-preventable diseases in observational studies.
| Study ID (year) | Vaccine type | Doses | HIV status | Vaccine effectiveness (%) | Adjusted vaccine effectiveness (%) | Disease of interest |
|---|---|---|---|---|---|---|
| Bhat (1993)24 | BCG | 1 | HI | 0 (−360 to 78) | Tuberculosis | |
| 1 | HU | 59 (8 to 82) | ||||
| Madhi (2002)26 | HibCV | 3 | HI | 43.9 (76.1 to 82.1) | Invasive Hib disease | |
| 3 | HU | 96.5 (74.4 to 99.5) | ||||
| Groome (2014)23 | Monovalent RV | 2 | HEU | 58% (16 to 79) | Acute rotavirus diarrhea | |
| 2 | HU | 52% (23 to 70) | ||||
| Cohen (2014)20 | PCV7 | ≥3 | HI | 43 (−108 to 85) | 57 (−371 to 96) | Invasive pneumococcal disease |
| ≥3 | HU | 57 (−100 to 91) | 90 (14 to 99) | |||
| Van-Dunem (2015)22 | BCG Connaught | 1 | HI | 8 (−26 to 32) | 30 (−75 to 72) | Tuberculosis |
| Bar-Zeev (2016)25 | Monovalent RV | 2 | HEU | 42.2% (−106.9–83.8) | Acute rotavirus diarrhea | |
| 2 | HU | 60.5% (13.3–82.0) | ||||
| Cohen (2017)21 | PCV13 | ≥2 | HI (overall) | 26% (–98 to 72) | 17% (–304 to 80) | Invasive pneumococcal disease |
| ≥2 | HI with severe immunosuppression | –42% (–723 to 76) | – 104% (–1433 to 73) | |||
| ≥2 | HI with no severe immunosuppression | 75% (–31 to 95) | 66% (–94 to 94) | |||
| ≥2 | HU (overall) | 83% (61 to 92) | 78% (46 to 91) | |||
| ≥2 | HEU | 91% (60 to 98) | 87% (38 to 97) |